-
1 week ago | 
ajmc.com | Jared Kaltwasser
Venetoclax (Venclexta; Abbvie, Genentech) has a high response rate in octogenarians with chronic lymphocytic leukemia (CLL), but clinicians should expect treatment-management challenges such as temporary stops.1Those are among the key findings of a new retrospective study that examined the safety and efficacy of the BCL-2 inhibitor in older patients. The report was published inBlood Advances.
-
1 week ago | 
ajmc.com | Jared Kaltwasser
Tarlatamab (Imdelltra; Amgen) led to improved survival outcomes compared with chemotherapy in patients with small cell lung cancer (SCLC) whose cancers progressed during or after platinum-based chemotherapy, a new report found. The study was published in The New England Journal of Medicine.1Tarlatamab is a bispecific T-cell engager that targets both delta-like ligand 3 (DLL3), which is expressed on the surface of cancer cells in most patients, and CD3, which is found on T-cells.
-
1 week ago | 
ajmc.com | Jared Kaltwasser
The use of teledermatology and dermoscopy is an effective strategy to screen patients for skin cancer in underserved communities who have suspicious lesions, a new study suggests.1The report is based on the experience of providers and patients at the Augusta Free Dermatology Clinic in rural Georgia. The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois.
-
1 week ago | 
managedhealthcareexecutive.com | Jared Kaltwasser
As new therapies become available to extend the lives of patients with Duchenne muscular dystrophy (DMD), a new report is highlighting the importance of educating caregivers on respiratory interventions. Eliza Wasilewska, M.D., Ph.D., of the Medical University of Gdansk, Poland, and colleagues said the extension of life expectancy for patients with DMD has brought about new challenges for caregivers.
-
2 weeks ago | 
ajmc.com | Jared Kaltwasser
A novel small molecule therapy for idiopathic pulmonary fibrosis (IPF) that was first identified using artificial intelligence (AI) was found to be safe and well-tolerated in a phase 2a trial.1 The results, published inNature Medicine, could lead to the development of one of the first new therapies attributable to generative AI, although longer, larger-scale trials are needed to confirm the initial findings.
-
2 weeks ago | 
ajmc.com | Jared Kaltwasser
Cemiplimab (Libtayo; Regeneron) showed efficacy in high-risk patients with cutaneous squamous cell carcinoma (CSCC) and in the real-world setting in abstracts from the 2025 American Society of Clinical Oncology (ASCO) annual meeting.1,2 Cemiplimab is a monoclonal antibody targeting PD-1, and it was approved by the FDA in 2018 for the treatment of metastatic or locally advanced CSCC.3 In clinical trials, 47% of patients had a response to therapy, and a majority of responders had a duration of...
-
2 weeks ago | 
ajmc.com | Jared Kaltwasser
Obesity is a major public health issue for adults, but for an increasing number of patients, its onset begins in childhood. One study found that more than half of children with obesity will remain obese in adolescence, and 80% of adolescents with obesity go on to have obesity in adulthood.1 Yet, despite the significant risk that obesity will bridge different phases of life, current guidelines tend to be broken up into discrete age categories.
-
2 weeks ago | 
ajmc.com | Jared Kaltwasser
Cytogenetic risk factors do not appear to affect survival outcomes following first-line ibrutinib (Imbruvica; Johnson & Johnson) among people with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), according to a new analysis of real-world survival data.1 The findings, published inBlood Advances, offer additional support for the use of ibrutinib as a first-line therapy in this patient group.
-
2 weeks ago | 
ajmc.com | Jared Kaltwasser
The timing of immunotherapy initiation does not play a major role in survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC), new research has found.1 The findings, which were presented in a poster session at the American Society of Clinical Oncology 2025 Annual Meeting in Chicago, showed patients who received immunotherapy alongside their first cycle of chemotherapy had similar progression-free survival (PFS) to those who received immunotherapy after their first...
-
2 weeks ago | 
managedhealthcareexecutive.com | Jared Kaltwasser
A new customized version of a common patient-reported outcomes instrument could make it easier to reliably assess upper-extremity function in children with Duchenne muscular dystrophy (DMD). The new assessment, an adapted version of the Patient-Reported Outcomes Measurement Information System (PROMIS) Parent Proxy Physical Function-Upper Extremity (PROMIS PP UE) instrument, was outlined in Frontiers in Neurology.
